



Corrigendum to 'Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development' Drug Discovery Today 23 (2018) 1733–1745

Shalini Andersson, Madeleine Antonsson, Marie Elebring, Rasmus Jansson-Löfmark and Lars Weidolf, Lars.Weidolf@astrazeneca.com



Drug Metabolism and Pharmacokinetics, Cardiovascular, Renal and Metabolism, Innovative Medicines Biotech Unit, AstraZeneca Gothenburg, SE-43183 Mölndal, Sweden

The authors regret that Fig. 1 (page 1736), representing the chemical development of modified nucleotides, is incorrectly drawn. A revised figure is provided.

The authors would like to apologise for any inconvenience caused.




FIGURE 1

Representation of the chemical development of modified nucleotides. Abbreviations: PO, phosphodiester; PS, phosphorothioate; Rp, R-configured PS; Sp, S-configured PS; 2'-X, -H (DNA), -OH (RNA), 2'-X modifications, -F, -OMe (methoxy), -MOE (methoxyethyl); base, DNA: guanine, adenine, cytosine, thymine and RNA: guanine, adenine, cytosine, uracil; LNA, locked nucleic acid; cEt, constrained ethyl nucleic acid; other: 4'-OMe, 5'-Me.

DOI of original article: [10.1016/j.drudis.2018.05.030](https://doi.org/10.1016/j.drudis.2018.05.030)
Corresponding author: Weidolf, L. (Lars.Weidolf@astrazeneca.com)